Clinical Trials Directory

Trials / Completed

CompletedNCT03660748

Safety and Efficacy of MET-3 in Obese Human Subjects

A Phase I, Open-Label, Single-Centre Study of the Safety and Efficacy of Microbial Ecosystem Therapeutics (MET)-3 in Obese Human Subjects

Status
Completed
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
15 (actual)
Sponsor
NuBiyota · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

A pilot study to explore the metabolic effect and safety of a 3-week course of therapy with MET-3 in obese subjects

Detailed description

This is an open label, single center, uncontrolled pilot study of 20 participants; each group will receive a different dose of MET-3. Each group will have 4-6 females, 4-6 participants with BMI 30.0-34.9 kg/m² and the remainder with BMI 35-39.9 kg/m.

Conditions

Interventions

TypeNameDescription
BIOLOGICALMET-2Ingestion of a novel human microbiome preparation

Timeline

Start date
2018-10-01
Primary completion
2020-01-22
Completion
2020-01-22
First posted
2018-09-07
Last updated
2020-08-11

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT03660748. Inclusion in this directory is not an endorsement.

Safety and Efficacy of MET-3 in Obese Human Subjects (NCT03660748) · Clinical Trials Directory